Emalex Biosciences
2 known investors
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced the asset through clinical development and was acquired by Teva Pharmaceutical Industries in 2026.
BiotechMedical Devices
Investors Β· 2
Frequently asked questions
- What does Emalex Biosciences do?
- Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced the asset through clinical development and was acquired by Teva Pharmaceutical Industries in 2026.
- Who are Emalex Biosciences's investors?
- Emalex Biosciences's investors include Paragon Biosciences LLC, Bain Capital Life Sciences.